These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8623216)

  • 1. Neoral in liver transplantation.
    Levy GA; Grant D
    Transplant Proc; 1996 Apr; 28(2):1019-21. PubMed ID: 8623216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoral therapy in liver transplantation.
    Levy GA
    Transplant Proc; 1996 Aug; 28(4):2225-8. PubMed ID: 8769206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.
    van Mourik ID; Thomson M; Kelly DA
    Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
    Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
    Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
    White M; Pelletier GB; Tan A; Jesina C; Carrier M
    J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of cyclosporine for liver transplantation.
    Lilly LB; Grant D
    Transplant Proc; 2004 Mar; 36(2 Suppl):267S-270S. PubMed ID: 15041351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation.
    Kesten S; Scavuzzo M; Chaparro C; Szalai JP
    Pharmacotherapy; 1998; 18(4):847-50. PubMed ID: 9692659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application?
    Haller GW; Winkler M; Bechstein WO; Oldhafer KJ; Ringe B; Maibücher A; Färber L; Pichlmayr R; Neuhaus P
    Transplant Proc; 1996 Aug; 28(4):2239-40. PubMed ID: 8769211
    [No Abstract]   [Full Text] [Related]  

  • 11. Neoral/cyclosporine-based immunosuppression.
    Levy GA
    Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S37-47. PubMed ID: 10431016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group.
    Hoyer PF
    Pediatr Transplant; 1998 Feb; 2(1):35-9. PubMed ID: 10084758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring of cyclosporine.
    Midtvedt K
    Transplant Proc; 2004 Mar; 36(2 Suppl):430S-433S. PubMed ID: 15041380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption of cyclosporine Neoral early after liver transplantation: influence of bile on oral absorption.
    Oldhafer K; Haller GW; Kattner A; Winkler M; Maibücher A; Färber L; Bechstein WO; Ringe B; Neuhaus P; Pichlmayr R
    Transplant Proc; 1996 Aug; 28(4):2237-8. PubMed ID: 8769210
    [No Abstract]   [Full Text] [Related]  

  • 15. Change of conventional cyclosporine to neoral cyclosporine formulation in long-term liver transplant recipients.
    Diliz HS; Olivera MA; Kershenobich D; Mercado MA; Orozco H
    Transplant Proc; 1996 Dec; 28(6):3348-50. PubMed ID: 8962302
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic drug monitoring of cyclosporine: 20 years of progress.
    Kahan BD
    Transplant Proc; 2004 Mar; 36(2 Suppl):378S-391S. PubMed ID: 15041372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoral in de novo liver transplantation: adequate immunosuppression without intravenous cyclosporine.
    Levy GA; Rasmussen A; Mayer AD; Jamieson NV; Neuhaus P
    Liver Transpl Surg; 1997 Nov; 3(6):571-7. PubMed ID: 9404955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients.
    Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J
    Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2.
    Cole E; Deshpande R
    Transplant Proc; 2004 Mar; 36(2 Suppl):408S-413S. PubMed ID: 15041376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
    Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
    J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.